DelveInsight’s “Prostate Cancer Pipeline Insight 2025” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight’s comprehensive Prostate Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes. 

Key Takeaways from the Prostate Cancer Pipeline Report
- In August 2025, Bayer conducted a study to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone‑sensitive prostate cancer.
- In July 2025, Merck Sharp & Dohme LLC announced a substudy to assess the efficacy and safety of ifinatamab deruxtecan (I‑DXd), given alone or with other treatments in participants with metastatic castration‑resistant prostate cancer (mCRPC).
- DelveInsight’s Prostate Cancer pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Prostate Cancer treatment.
- The leading Prostate Cancer Companies include Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, and Cellbion Co., Ltd., and others.
- Promising Prostate Cancer Pipeline such as Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F‑PSMA‑1007, rhPSMA‑7.3 (18F) Injection, and others.

Prostate Cancer Emerging Drugs
- Niraparib: Janssen Research & Development – An orally administered selective PARP inhibitor currently in Phase III trials for metastatic castration‑resistant and hormone‑sensitive prostate cancer.
- ZEN‑3694: Zenith Epigenetics – An orally bioavailable BET inhibitor in Phase II trials for prostate cancer.
- Ladiratuzumab vedotin: Seagen – An ADC targeting LIV‑1 in Phase II trials for prostate cancer.
- FOR46: Fortis Therapeutics – A fully human antibody‑drug conjugate against CD46 in Phase I/II trials for prostate cancer.
- REGN5678: Regeneron Pharmaceuticals – A bispecific targeting CD28 on T‑cells and PSMA on tumor cells in Phase I/II trials for prostate cancer.

The Prostate Cancer Pipeline report provides insights into companies developing therapies, therapeutic candidate segmentation, collaborations, licensing agreements, and financing details.

Prostate Cancer Companies
Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol‑Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc.

Scope of the Prostate Cancer Pipeline Report
- Coverage: Global
- Prostate Cancer Companies: listed above
- Prostate Cancer Pipeline: Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F‑PSMA‑1007, rhPSMA‑7.3 (18F) Injection, and others.
- Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre‑clinical, Phase I, Phase II, Phase III

About Us
DelveInsight is a leading healthcare‑focused market research and consulting firm that provides clients with high‑quality market intelligence and analysis. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: (not provided)
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Website: (not provided)

Press Release Distributed by ABNewswire.com

Prostate Cancer Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s 2025 prostate cancer pipeline report outlines over 140 companies and 150+ drug candidates, highlighting recent studies by Bayer and Merck, and detailing several Phase I‑III therapies from Janssen, Zenith Epigenetics, Seagen, Fortis Therapeutics, and Regeneron.